Publication details

Analysis of serum lipids, cardiovascular risk, and indication for statin use during nilotinib and imatinib therapy in de novo CML patients ? results from real-life prospective study

Authors

HORŇÁK Tomáš SEMERÁD Lukáš ŽÁČKOVÁ Daniela WEINBERGEROVÁ Barbora ŠUSTKOVÁ Zuzana PROCHÁZKOVÁ Jiřina BELOHLAVKOVA Petra STEJSKAL Lukas ROHON Peter FABER Edgar ZAK Pavel MAYER Jiří RÁČIL Zdeněk

Year of publication 2020
Type Article in Periodical
Magazine / Source LEUKEMIA & LYMPHOMA
MU Faculty or unit

Faculty of Medicine

Citation
Web https://www.tandfonline.com/doi/full/10.1080/10428194.2019.1672054
Doi http://dx.doi.org/10.1080/10428194.2019.1672054
Keywords serum lipids; cardiovascular risk; nilotinib and imatinib therapy
Description Tyrosine kinase inhibitors (TKI) have dramatically improved the prognosis of CML patients with life expectancy close to individuals without CML [1], and therefore the longterm safety of TKIs has become especially important due to the potential for lifelong treatment. Nilotinib (NILO) tends to have a negative effect on lipid [2] and glucose [3] metabolism, while imatinib (IMA) seems to improve [4] these abnormalities. Although the data appear convincing, the real impact of these changes on cardiovascular (CV) risk and the development of CV complications during TKI therapy have not yet been confirmed.
Related projects: